Clinical Trials Browser

Phase 2 × Hodgkin Disease × Ipilimumab × Clear all

NCT04938232 2026-02-05

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Phase 2 Active not recruiting

13 enrolled 19 charts

Hodgkin Disease